In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $3.20.
According to TipRanks, Chen is an analyst with an average return of -30.0% and a 24.65% success rate. Chen covers the Healthcare sector, focusing on stocks such as Clearside Biomedical, First Wave Bio, and Anixa Biosciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Anixa Biosciences with a $10.50 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $6.45 and a one-year low of $2.77. Currently, Anixa Biosciences has an average volume of 106.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
